This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Enoximone Oral

Gilead Sciences, Inc.

Drug Names(s): Enoximone Oral

Description: BioMedTracker has separate drug profiles for the oral and intravenous formulations of Enoximone. Please also see Perfan I.V.

Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

Deal Structure: Myogen and Sanofi
In 1999, Myogen obtained from Hoechst Marion Roussel (now Sanofi-Aventis) an exclusive worldwide license under Sanofi-Aventis' patents and know-how to develop and commercialize Enoximone and (b) all of Sanofi-Aventis' rights under certain existing trademarks relating to Enoximone in several countries around the world. Gilead announced it completed of its cash tender offer for all of the outstanding shares of common stock of Myogen on November 14th, 2006. On October 2, 2006, Gilead and Myogen entered into a definitive merger agreement for Gilead to acquire all of the outstanding shares of common stock of Myogen for $52.50 in cash per share.

Gilead and MyogenGilead announced it completed of its cash tender offer for all of the outstanding shares of common stock of Myogen on November 14th, 2006. On October 2, 2006, Gilead and Myogen entered into a definitive merger agreement for Gilead to acquire all of the outstanding shares of common stock of...See full deal structure in Biomedtracker

Partners: Sanofi


Enoximone Oral News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug